VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ZNTL
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ZNTLZentalis Pharmaceuticals, Inc.
$1.49$106M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksZNTLBalance Sheet

Zentalis Pharmaceuticals, Inc. (ZNTL) Balance Sheet

8Y historyFree accessUpdated daily

Total debt of roughly $33.6M against equity of $143.6M yields a D/E of 0.23, which appears modest, but this headline ratio may understate risk as equity shrank from $458.8M in 2024Q1 and cash fell to $24.8M.

Income StatementBalance SheetCash FlowRatios

ZNTL Balance Sheet

Annual statement

ZNTL Balance Sheet

Zentalis Pharmaceuticals, Inc. (ZNTL) balance sheet — 8-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18
Total Current Assets237.27M253.19M386.07M496.72M451.93M350.77M345.1M68.89M26.68M
Cash & Short-Term Investments228.89M245.89M371.08M482.92M437.37M340.13M338.5M67.25M25.15M
Cash Only24.03M35.99M33.9M28.04M43.07M59.96M54.95M67.25M25.15M
Short-Term Investments204.86M209.9M337.18M454.88M394.3M280.17M283.55M00
Accounts Receivable01.93M5M002.63M0140K917K
Days Sales Outstanding--27.07-----23.91K
Inventory000000000
Days Inventory Outstanding---------
Other Current Assets05.37M013.8M14.56M0417K00
Total Non-Current Assets32.92M35.78M44.27M65.31M101.52M121.25M20.45M19.34M14.32M
Property, Plant & Equipment26.18M29.04M37.23M41.73M50.08M52.84M3.62M2.84M260K
Fixed Asset Turnover0.00x-1.81x-----0.05x
Goodwill0003.74M3.74M3.74M3.74M3.74M3.74M
Intangible Assets0000008.8M8.8M8.8M
Long-Term Investments5.25M02.63M2.68M23.84M40.12M0243K-46.26K
Other Non-Current Assets6.74M6.74M4.42M6.82M9.72M7.04M4.3M2.97M1.52M
Total Assets270.19M288.97M430.34M562.03M553.46M472.02M365.56M88.23M41M
Asset Turnover0.00x-0.16x-----0.00x
Asset Growth %-123.16%-32.85%-23.43%1.55%17.25%29.13%314.31%115.21%-
Total Current Liabilities32.36M36.56M52.73M69.37M56.65M43.94M28.6M14.9M6.21M
Accounts Payable5.33M7.21M7.44M14.93M11.25M11.59M8.66M4.29M3.43M
Days Payables Outstanding16.96K--------
Short-Term Debt03.87M3.07M2.62M01.45M0781K0
Deferred Revenue (Current)000281K0000223.42K
Other Current Liabilities015.51M29.42M-2.9M384K20.68M410K6.85M223K
Current Ratio7.33x6.93x7.32x7.16x7.98x7.98x12.07x4.62x4.30x
Quick Ratio7.33x6.93x7.32x7.16x7.98x7.98x12.07x4.62x4.30x
Cash Conversion Cycle---------
Total Non-Current Liabilities32.94M36.2M40.43M55.27M62.79M63.6M3.58M4.91M2.48M
Long-Term Debt000000000
Capital Lease Obligations101.7M35.7M39.58M43.15M45.17M44.46M1.1M1.7M0
Deferred Tax Liabilities00010.34M15M19.14M03.21M2.46M
Other Non-Current Liabilities500K500K849K1.78M2.62M02.48M5K21K
Total Liabilities65.31M72.76M93.15M124.64M119.43M107.54M32.18M19.81M8.69M
Total Debt36.71M39.58M42.65M45.77M47.33M45.91M2M2.48M0
Net Debt12.68M3.58M8.75M17.73M4.26M-14.04M-52.95M-64.77M-25.15M
Debt / Equity0.18x0.18x0.13x0.10x0.11x0.13x0.01x0.04x-
Debt / EBITDA-0.24x--------
Net Debt / EBITDA-0.08x--------
Interest Coverage-----91.26x----
Total Equity204.89M216.2M337.19M437.39M434.02M364.48M333.38M68.42M32.31M
Equity Growth %-140.68%-35.88%-22.91%0.78%19.08%9.33%387.24%111.79%-
Book Value per Share2.423.014.746.698.218.548.121.911.79
Total Shareholders' Equity204.89M216.2M337.19M437.28M433.8M363.95M308.58M61.6M24.77M
Common Stock98K69K71K70K59K45K41K2.89M2.27M
Retained Earnings-1.3B-1.19B-1.05B-888.56M-596.37M-359.56M-200.83M-82.99M-37.33M
Treasury Stock000000000
Accumulated OCI-495K196K558K2.19M-1.35M-125K36K0-56K
Minority Interest000107K221K528K24.8M6.82M7.54M

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetStrained
Cash FlowBurning
Top Statement Risk

Shrinking cash cushion against burn

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Asset Base Shrinking Steadily Over Time

According to the reported quarterly balance sheets, ZNTL's total assets fell from $557.5M in 2024Q1 to $215.3M in 2026Q2, a decline of roughly 61 percent that tracks the company's sustained operating losses.

The contraction is driven primarily by cash consumption rather than any asset repositioning, since goodwill was written off entirely and PPE has remained small. Equity has fallen from $458.8M to $143.6M over the same period, which suggests the balance sheet is weakening as a direct function of the burn rate. Investors should monitor whether the trajectory implies a need for external capital before the next clinical or regulatory milestone.

Current Ratio Masks Thinning Cash Runway

Based on reported figures, ZNTL's current ratio remains elevated at 4.82 in 2026Q2, yet cash has declined from $41.9M in 2025Q1 to $24.8M, leaving a much thinner buffer than the ratio alone implies.

A high current ratio here reflects the modest size of current liabilities relative to the remaining liquid base rather than a deep reservoir of cash. Given free cash flow in the range of negative $27M to negative $70M per quarter, the reported cash position may cover only a limited number of quarters of operating burn. This warrants further investigation into the timing of cash needs relative to the company's pipeline commitments.

Low Leverage Reflects Limited Borrowing Capacity

As reported in the financial statements, ZNTL's debt-to-equity ratio has risen from 0.10 to 0.23 while total debt stayed near $34M to $45M, indicating leverage is increasing mainly because equity is shrinking.

The rising D/E ratio is an artifact of equity erosion rather than new borrowing, which is a meaningful distinction for interpreting leverage. Modest absolute debt levels suggest the company has not relied heavily on credit to fund operations, but the absence of a larger debt base may also reflect constrained access to lenders for a loss-making biotech. The key monitoring point is whether declining equity eventually pressures debt covenants or refinancing terms.

Accumulated Deficit Dominates Equity Structure

Based on the reported retained earnings line, ZNTL's accumulated deficit deepened from -$878.5M in 2024Q1 to roughly -$1.3B in 2026Q2, which is the principal driver of the equity decline.

The equity base is being eroded almost entirely by cumulative losses, with stock-based compensation adding a non-cash component that is not captured in cash burn figures. Reported stock-based compensation of $31.4M in 2024Q4 and $6.4M in 2026Q2 indicates ongoing equity-linked cost that may imply future dilution. Investors should monitor share count changes as a potential transfer of value from existing holders.

Low Debt Is Not Balance Sheet Safety

Based on reported figures, ZNTL's modest D/E of 0.23 may appear reassuring, but the headline leverage ratio understates risk because the company's equity cushion and cash runway are both declining simultaneously.

A low leverage ratio can be misleading when the denominator, equity, is shrinking faster than debt is changing, and that dynamic is evident here. The more relevant risk is the combination of falling cash, persistent negative free cash flow, and the absence of reported revenue, which together suggest dependence on future financing. This is an analytical inference from the reported data rather than a disclosed fact about the company's funding plans.

ZNTL — Frequently Asked Questions

Quick answers to the most common questions about buying ZNTL stock.

What are the total assets of Zentalis Pharmaceuticals, Inc. (ZNTL)?

As of 2025, Zentalis Pharmaceuticals, Inc. (ZNTL) had total assets of $289.0M including $253.2M in current assets.

How much debt does Zentalis Pharmaceuticals, Inc. (ZNTL) have?

Zentalis Pharmaceuticals, Inc. (ZNTL) carries total debt of $39.6M, offset by $245.9M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Zentalis Pharmaceuticals, Inc.?

Zentalis Pharmaceuticals, Inc. (ZNTL) has total shareholders' equity (book value) of $216.2M ($3.01 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Zentalis Pharmaceuticals, Inc.'s current ratio and liquidity?

Zentalis Pharmaceuticals, Inc. (ZNTL) reported a current ratio of 6.93x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.